

Morton Aaron Scheinberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1562600/publications.pdf>

Version: 2024-02-01

70
papers

1,237
citations

430442

18
h-index

395343

33
g-index

73
all docs

73
docs citations

73
times ranked

1547
citing authors

#	ARTICLE	IF	CITATIONS
1	A Critical Analysis of the First Latin American Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e312-e316.	0.5	0
2	Knowledge gap about immune checkpoint inhibitors among rheumatologists and medical students: a survey. <i>Rheumatology International</i> , 2021, 41, 939-942.	1.5	3
3	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021, 60, 256-262.	0.9	14
4	Lupus low disease activity (SLE) in patients treated with belimumab: a single-center real-life experience (2016-2019). <i>Clinical Rheumatology</i> , 2021, 40, 923-927.	1.0	5
5	Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review. <i>Future Science OA</i> , 2021, 7, FSO655.	0.9	3
6	Tofacitinib-induced remission simultaneously in arthritis and vitiligo. <i>European Journal of Rheumatology</i> , 2021, 8, 55-56.	1.3	5
7	The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations. <i>Lupus</i> , 2021, 30, 1684-1695.	0.8	7
8	Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100099.	2.0	20
9	Chronic Inguinal Lymphadenitis in a Patient With Rheumatoid Arthritis Being Treated With Tofacitinib. <i>Journal of Clinical Rheumatology</i> , 2020, 26, e138-e139.	0.5	1
10	Atopic dermatitis: Tofacitinib, an option for refractory disease. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3243-3246.	0.2	6
11	Full histological and clinical regression of morphea with tofacitinib. <i>Clinical Rheumatology</i> , 2020, 39, 2827-2828.	1.0	6
12	Steroid-resistant sarcoidosis treated with baricitinib. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1259-1260.	0.5	15
13	Negative specificity for DSF70 in ANA positive leprosy sera. <i>Clinical Rheumatology</i> , 2019, 38, 2953-2955.	1.0	0
14	Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 701-711.	1.3	25
15	An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: a case report and a review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2539-2542.	0.2	11
16	The future landscape of biosimilars in rheumatology: Where we are where we are going. <i>Autoimmunity Reviews</i> , 2019, 18, 203-208.	2.5	9
17	Clinical evidence guidelines in systemic lupus erythematosus: reevaluation. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e119-e119.	0.5	2
18	Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products. <i>MAbs</i> , 2018, 10, 166-176.	2.6	20

#	ARTICLE	IF	CITATIONS
19	Belimumab in the treatment of systemic lupus erythematosus: An evidence based review of its place in therapy. <i>Autoimmunity Reviews</i> , 2018, 17, 103-107.	2.5	25
20	Summary of baricitinib effect on patient-reported outcomes (PROs) in methotrexate-inadequate responder patient population. <i>Rheumatology</i> , 2018, 57, .	0.9	0
21	Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptoms. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2775-2783.	2.0	2
22	Partnership for productive development of biosimilar products: perspectives of access to biological products in the Brazilian market. <i>Einstein (Sao Paulo, Brazil)</i> , 2018, 16, eRW4175.	0.3	5
23	Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America. <i>MAbs</i> , 2018, 10, 827-842.	2.6	5
24	Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-two-Week Randomized, Double-blind, Placebo-controlled Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 1016-1027.	2.9	287
25	Recovery of nail dystrophy potential new therapeutic indication of tofacitinib. <i>Clinical Rheumatology</i> , 2017, 36, 971-973.	1.0	13
26	Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. <i>Current Rheumatology Reports</i> , 2017, 19, 37.	2.1	79
27	Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series. <i>Rheumatology and Therapy</i> , 2017, 4, 503-508.	1.1	15
28	Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report. <i>Case Reports in Dermatology</i> , 2017, 8, 262-266.	0.3	25
29	A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1598-1602.	0.5	54
30	Difference between Enbrel and Benepali treatment groups in hepato-biliary disorders™. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e64-e64.	0.5	9
31	Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. <i>Clinical Rheumatology</i> , 2016, 35, 1719-1723.	1.0	27
32	The NICE position on indications for biologics and biosimilars. <i>Nature Reviews Rheumatology</i> , 2016, 12, 255-256.	3.5	2
33	Reversal of Alopecia Universalis by Tofacitinib: A Case Report. <i>Annals of Internal Medicine</i> , 2016, 165, 750.	2.0	14
34	Is Etaner a new biologic?. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 954.	0.4	2
35	Comparison of thromboprophylaxis patterns in arthroplasty in public and private hospitals. <i>Einstein (Sao Paulo, Brazil)</i> , 2015, 13, 410-416.	0.3	0
36	Bone health in cerebral palsy and introduction of a novel therapy. <i>Einstein (Sao Paulo, Brazil)</i> , 2015, 13, 555-559.	0.3	9

#	ARTICLE	IF	CITATIONS
37	Uma nova era na terapia em psoríase e artrite psoriática: novos mecanismos de ação e a introdução de biosimilares. Revista Brasileira De Reumatologia, 2015, 55, 469-470.	0.8	2
38	Facing up to biosimilar agents – the ACR position. Nature Reviews Rheumatology, 2015, 11, 322-324.	3.5	2
39	Use of rituximab as a treatment for systemic lupus erythematosus: retrospective review. Einstein (Sao Paulo) 11(1):103-110, 2015.	0.784314	10
40	When anti-TNF fails, anti-IL12-23 is an alternate option in psoriasis and psoriatic arthritis. Revista Brasileira De Reumatologia, 2014, 54, 247-249.	0.7	3
41	Disappearance of cryoproteins in the sera of a patient with SLE after treatment with blisibimod, a novel subcutaneous anti-B cell therapy. Rheumatology, 2014, 53, 957-958.	0.9	4
42	Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice. Arthritis Research and Therapy, 2014, 16, 501.	1.6	21
43	Real life experience on the effect of Belimumab in patients with active systemic lupus. SpringerPlus, 2014, 3, 758.	1.2	17
44	Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag. Clinical Rheumatology, 2014, 33, 1347-1349.	1.0	12
45	Biosimilars in Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 710.	0.6	5
46	Quando anti-TNF não obtém sucesso, anti-IL12-23 é opção alternativa na psoríase e na artrite psoriática. Revista Brasileira De Reumatologia, 2014, 54, 247-249.	0.8	4
47	Leishmaniasis during anti-tumor necrosis factor therapy: Report of 4 cases and review of the literature (additional 28 cases). Seminars in Arthritis and Rheumatism, 2013, 43, 152-157.	1.6	39
48	Taxas de retenção de infliximabe e tocilizumabe no período de 3 anos em um hospital brasileiro. Einstein (Sao Paulo, Brazil), 2013, 11, 492-494.	0.3	6
49	Failure to Control Progression of Rheumatoid Arthritis After a Decade of Biologic Therapy. Journal of Rheumatology, 2012, 39, 2049-2050.	1.0	0
50	The development of arthritis and antinuclear antibodies correlate with serum 25-hydroxyvitamin D levels in patients with leprosy. Annals of the Rheumatic Diseases, 2012, 71, 2062-2063.	0.5	13
51	Biosimilars in rheumatology: a view from Latin America. Clinical Rheumatology, 2012, 31, 1279-1280.	1.0	21
52	Aspergillus fumigatus Joint Infection: A Review. Seminars in Arthritis and Rheumatism, 2011, 40, 580-584.	1.6	24
53	Decreased need of large joint replacement in patients with rheumatoid arthritis in a specialized Brazilian center. Clinical Rheumatology, 2011, 30, 549-550.	1.0	6
54	A presença da reumatologia brasileira no GRAPPA (Group for Research and Assessment of Psoriasis) Tj ETQq0 0 0 ggBT /Overlock 10 Tt	0.8	2

#	ARTICLE	IF	CITATIONS
55	Yellow fever revaccination during infliximab therapy. <i>Arthritis Care and Research</i> , 2010, 62, 896-898.	1.5	59
56	Diagnosis of growing pains in a Brazilian pediatric population: a prospective investigation. <i>Einstein (Sao Paulo, Brazil)</i> , 2010, 8, 430-432.	0.3	5
57	Total hip and knee joint replacement: perioperative clinical aspects. <i>Einstein (Sao Paulo, Brazil)</i> , 2010, 8, 350-353.	0.3	12
58	The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease. <i>Rheumatology</i> , 2010, 49, 1014-1016.	0.9	20
59	Anti-interleukin 6: first line in rheumatoid arthritis?. <i>Clinical Rheumatology</i> , 2009, 28, 877-879.	1.0	3
60	Alterations in Cytokine Profile and Dendritic Cells Subsets in Peripheral Blood of Rheumatoid Arthritis Patients before and after Biologic Therapy. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 334-342.	1.8	24
61	Fibromyalgia: An update and immunological aspects. <i>Current Pain and Headache Reports</i> , 2008, 12, 321-326.	1.3	4
62	Anticitrulline peptide antibodies (CCP3) in leprosy sera: a negative association. <i>Clinical Rheumatology</i> , 2008, 27, 515-516.	1.0	17
63	Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, São Paulo, Brazil. <i>Clinical Rheumatology</i> , 2008, 27, 1049-1052.	1.0	11
64	The Enigmatic Development of Psoriasis and Psoriasiform Lesions During Anti-TNF Therapy: A Review. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 251-255.	1.6	58
65	Why do some biologic agents induce psoriasis or psoriasiform lesions?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 168-169.	3.2	11
66	(18) F-FDG PET Imaging of Rheumatoid Articular and Extraarticular Synovitis. <i>Journal of Clinical Rheumatology</i> , 2008, 14, 307.	0.5	10
67	Development of Serum Sickness-Like Symptoms After Rituximab Infusion in Two Patients With Severe Hypergammaglobulinemia. <i>Journal of Clinical Rheumatology</i> , 2007, 13, 94-95.	0.5	34
68	Ganciclovir-resistant, cytomegalic interstitial lung disease in a patient with systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2007, 26, 1753-1755.	1.0	3
69	The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept. <i>Clinical Rheumatology</i> , 2007, 27, 105-106.	1.0	18
70	Unexpected onset of psoriasis during infliximab treatment: Comment on the article by Beuthien et al. <i>Arthritis and Rheumatism</i> , 2005, 52, 1333-1334.	6.7	30